Atara Biotherapeutics Inc (NASDAQ:ATRA) – Equities researchers at William Blair boosted their Q1 2018 EPS estimates for shares of Atara Biotherapeutics in a research report issued to clients and investors on Tuesday. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($0.89) per share for the quarter, up from their prior estimate of ($1.08). William Blair also issued estimates for Atara Biotherapeutics’ Q2 2018 earnings at ($0.88) EPS, Q3 2018 earnings at ($0.90) EPS, Q4 2018 earnings at ($0.92) EPS, FY2018 earnings at ($3.59) EPS, FY2019 earnings at ($4.00) EPS, FY2020 earnings at ($3.06) EPS and FY2021 earnings at ($2.20) EPS.

Get Atara Biotherapeutics alerts:

Other equities analysts have also recently issued reports about the company. Citigroup cut Atara Biotherapeutics from a “neutral” rating to a “sell” rating in a report on Thursday. ValuEngine raised Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub cut Atara Biotherapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 3rd. Canaccord Genuity reissued a “positive” rating and set a $70.00 price target (up previously from $47.00) on shares of Atara Biotherapeutics in a report on Friday, January 19th. Finally, Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 6th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Atara Biotherapeutics currently has a consensus rating of “Hold” and an average price target of $30.60.

Atara Biotherapeutics (ATRA) opened at $48.35 on Thursday. The firm has a market capitalization of $1,693.69, a price-to-earnings ratio of -13.93 and a beta of 2.71. Atara Biotherapeutics has a fifty-two week low of $11.80 and a fifty-two week high of $49.90.

In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 20,000 shares of the company’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $46.80, for a total value of $936,000.00. Following the sale, the chief executive officer now owns 808,675 shares in the company, valued at approximately $37,845,990. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the company’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $14.25, for a total value of $62,700.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 297,914 shares of company stock valued at $8,074,587. Insiders own 16.20% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at about $142,000. Russell Investments Group Ltd. bought a new stake in shares of Atara Biotherapeutics in the 3rd quarter valued at about $170,000. Voya Investment Management LLC grew its position in shares of Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 1,651 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock valued at $285,000 after buying an additional 1,369 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock valued at $304,000 after buying an additional 610 shares during the last quarter. Hedge funds and other institutional investors own 69.58% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics Inc (ATRA) to Post Q1 2018 Earnings of ($0.89) Per Share, William Blair Forecasts” was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.chaffeybreeze.com/2018/02/15/atara-biotherapeutics-inc-atra-to-post-q1-2018-earnings-of-0-89-per-share-william-blair-forecasts.html.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.